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Abstract Breast invasive micropapillary carcinoma (IMPC)
is a rare subtype of breast cancer with a high potential of
lymph node metastasis, aggressive clinical behavior, and poor
disease-free or overall survival. Expression of leucine zipper
putative tumor suppressor 1 (LZTS1) was frequently lost or
reduced in breast cancer tissues. This study investigated the
expression of LZTS1 protein in breast IMPC tissues using
immunohistochemistry. In addition, somatic LZTS1mutations
and promoter methylation were assessed to determine an as-
sociation with clinicopathological data from IMPC patients.
LZTS1 protein was downregulated in 62 (62 %) of 100 IMPC
tissue samples and was significantly associated with lymph
node metastasis (P<0.05). A LZTS1 exon mutation occurred
in one of the 53 IMPC cases analyzed, whereas a LZTS1 intron
mutation occurred in 26 of 53 cases. Moreover, LZTS1 pro-
moter was frequently methylated in IMPC samples and was
associated with reduced LZTS1 expression levels in IMPC
tissues. These data demonstrated that the loss of LZTS1 ex-
pression was associated with lymph node metastasis in pa-
tients with IMPC, and LZTS1 promoter methylation could be
responsible for the loss of LZTS1 expression.
Keywords Breast IMPC . LZTS1 . Gene expression and
promoter methylation
Abbreviations
LZTS1 Leucine zipper putative tumor suppressor 1
IMPC Invasive micropapillary carcinoma
IDC Invasive ductal carcinoma
DHPLC Denaturing high performance liquid
chromatography
Introduction
Breast cancer is the most frequently diagnosed cancer in wom-
en, accounting for 1.4 million new cases and an estimated
more than 458,000 cancer-related deaths in 2008 worldwide
(Global Cancer Facts & Figures, 2nd Edition, American Can-
cer Society). Early stage breast cancer typically is not associ-
ated with symptoms. Risk factors of breast cancer include
female gender, old age, inherited mutations (such as BRCA1
and BRCA2), family history of breast cancer, high breast tis-
sue density, overweight or obese after menopause, use of men-
opausal hormone therapy (MHT), physical inactivity, and al-
cohol consumption (Global Cancer Facts & Figures, 2nd Edi-
tion, American Cancer Society). These risk factors could ac-
tivate oncogenes and silence tumor suppressor genes, leading
to the development of breast cancer [1]. Moreover, the cause
of death for breast cancer patients is usually due to metastasis.
Thus, the most important prognostic factor in breast cancer
remains the lymph node status, which strongly correlates with
disease-free and overall survival of the patients.
Clinically, breast cancer is classified as carcinoma in situ or
invasive ductal carcinoma (IDC). Histologically, the vast
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majority of breast cancer is characterized as IDC. Invasive
micropapillary carcinoma (IMPC) is a rare subtype of IDC
and was listed by the World Health Organization classification
in 2003 [2]. The incidence of IMPC is approximately 4.18 %,
and IMPC is frequently mixed with IDC, not otherwise speci-
fied (NOS) and a pure IMPC is the micropapillary component
≥90 %. In addition, IMPC is associated with a high invasion
potential to lymphatic vessels and metastasis to the axillary
lymph nodes [3–5]. However, the underlying mechanisms are
poorly understood.
Leucine zipper putative tumor suppressor 1 (LZTS1) was
identified by Ishii et al. in 1999 [6]. Ubiquitous expression of
LZTS1 protein has been detected in normal tissues; however, it
is reduced or lost in different cancer tissues and cells, including
gastric, lung, bladder, oral, and kidney cancers [6–13]. Restora-
tion of LZTS1 expression in LZTS1-negative cancer cells result-
ed in the suppression of tumorigenicity, reduced tumor cell
growth, and arrested cells at the late S-G2/M phase of the cell
cycle. Previous studies have shown that LZTS1 expression
levels are downregulated in breast cancer tissue and cell lines
[14]. Our own data confirmed that LZTS1 expression was re-
duced or lost in IDC, and reduced LZTS1 expression was asso-
ciated with lymph node metastasis [15]. Hypermethylation of
LZTS1 CpG islands could be responsible for the reduced ex-
pression of LZTS1 in cancer cells [7, 8]. In this study, we de-
tected the expression of LZTS1 protein in IMPC tissues using
immunohistochemistry. In addition, we determined whether so-
matic LZTS1 mutations and promoter methylation were associ-
ated with clinicopathological data from IMPC patients.
Materials and Methods
Study Population
In total, 100 pure IMPC breast tissue specimens and 20 normal
breast tissues (used as a control) were retrospectively retrieved
from The Department of Breast Cancer Pathology and
Research Laboratory of the Cancer Hospital of Tianjin Medical
University in Tianjin, China. These patients were surgically
treated in our hospital between October 2005 and December
2009 and histologically diagnosed as IMPC, independently by
two pathologists using the WHO criteria [1]. Since our previ-
ous study demonstrated that IMPCwas significantly associated
with lymph nodes metastasis [16], we grouped them as a single
disease entity for this study. All of the patients were women
with a mean age of 54 years (range: 29–83 years). None of the
patients received preoperative radiation or chemotherapy. Use
of human tissue in this study was approved by the Ethics Com-
mittee of the Tumor Hospital of Tianjin Medical University,
and each patient signed a inform consent.
Immunohistochemistry
Formalin-fixed and paraffin-embedded tissue blocks were cut
into sections. For immunohistochemistry, the tissue sections
were first deparaffinized in xylene and rehydrated in a series
of graded alcohol. For antigen retrieval, the sections were sub-
merged in 5 mM citrate buffer (pH 6.0), cooked for 1.5 min in a
pressure cooker, and then incubated with 3 % H2O2 in phos-
phate buffered saline (PBS) at the room temperature for 30 min
to inactivate endogenous peroxidase. The sections were further
incubated with 10 % normal rabbit serum for 10 min to block
non-specific binding of the secondary antibody. Next, the sec-
tions were incubated with a polyclonal goat anti-LZTS1 anti-
body (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at a
dilution of 1:75 at 4 °C overnight. The negative control section
was incubated with a preimmune serum to replace the antibody.
On the next day, the sections were washed with PBS thrice,
incubated with a biotinylated anti-goat antibody, and then in-
cubated with streptavidin-biotin-peroxidase (Zhongshan Gold-
en Bridge, Beijing, China). Diaminobenzidine was used as a
chromogen substrate to visualize the positive signal. Then, the
sections were washed in distilled water and shortly counter-
stained with hematoxylin and mounted. The sections were fi-
nally reviewed under a microscope independently by two
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pathologists and blindly scored for LZTS1 immunoreactivity
into four categories using a previously reported scoring method
[9]: +++ or strong (96–100 % positive cells); ++ or moderate
(51–95 % positive cells); + or weak (2–50 % positive cells);
and—or absent (<2 % positive cells).
Denaturing High Performance Liquid Chromatography
(DHPLC) Analysis
We performed DHPLC analysis to sequence LZTS1mutations.
We designed different primers to amplify the coding regions of
the three exons of LZTS1 (Table 1). Genomic DNAwas extract-
ed form paraffin sections using a DNA tissue kit (Qiagen, Ger-
many) according to the manufacturer’s instructions and then
subjected to PCR amplification using AmpliTaq Gold (Applied
Biosystems, USA) in a final volume of 25 ml. The system
control software (Transgenomic Navigator Software,
Transgenomic, USA) gave the running conditions of each
amplicon. PCR product was applied to a DNASep column
(Transgenomic-Wave 3500A DHPLC system, Transgenomic).
All of the PCR products that produced tumor-specific shifts on
DHPLC were re-amplified and sequenced with both forward
and reverse primers using BigDye sequencing chemistry (Ap-
plied Biosystems). The PCR products that resulted in DHPLC
shifts with both tumor and germline DNAwere also sequenced
to identify polymorphisms.
Bisulfite Treatment, Methylation-Specific PCR (MSP),
and DNA Sequencing
We treated genomic DNAwith bisulfite as previously described
[17]. Briefly, 2 g of genomic DNA was diluted into 50 ml of
distilled water and 5.5 ml of 2MNaOHwas added. The mixture
was then incubated at 37 °C for 10 min. After that, 30 ml of
freshly prepared 10 mM hydroquinone (Sigma, St Louis, MO,
USA) and 520 ml of freshly prepared 3 M sodium bisulfite
(pH 5.0) (Sigma) were added to each tube. After thorough
mixing, mineral oil was added to each tube. The tubes were
incubated at 50 °C for 16 h. On the next day, 1ml of DNAwizard
cleanup resin was added (Promega, Madison, WI, USA). The
modified genomic DNAwas purified and eluted with 50 ml of
water following the instructions in the kit. After adding 5.5 ml of
3MNaOHand incubating at room temperature for 5min, 1ml of
glycogen (Sigma, St Louis,MO,USA)was added to each sample
and then precipitated with 33 ml of 10 M NH4Ac (Sigma) and
three volumes of ethanol. The DNA samples were then re-
suspended in 20 ml distilled water and stored at −20 °C until use.
For the MSP analysis of LZTS1 promoter CpG methylation,
we designed two pairs of primers to cover the CpG enriched
region of the LZTS1 promoter as described previously [15].
PCR amplification was performed in a volume of 25 ml contain-
ing 2 ml of bisulfite-treated DNA. The PCR cycles consisted of
an initial denaturing at 94 °C for 5 min, followed by 40 cycles of
94 °C for 20 s, 60 °C for 20 s and 72 °C for 30 s, and a final step
at 72 °C for 5min. PCRproducts were then cloned into a pGEM-
Fig. 1 Immunohistochemical
detection of LZTS1 expression in
normal breast, and IMPC tissues.
a and b Expression of LZTS1
protein in the cytoplasm of
normal breast ductal epithelia. c
Strong expression (+++) of
LZTS1 protein in IMPC tissues. d
Absence of LZTS1 protein in
IMPC tissue. a, c, d at ×100
magnification and b at ×400
magnification
Table 2 LZTS1 expression in IMPC and normal breast tissues
Pathologic type LZTS1 expression χ2 P value
−/+ ++/+++
IMPC 62 38
Normal 0 20 25.655 0.000
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T Easy Vector (Promega), and DNA was sequenced by
Invitrogen (Carlsbad, CA, USA).
Statistical Analysis
Statistical analyses were performed using a Mann–WhitneyU
test, Spearman’s Rank-Correlation test, Student’s t test and χ2
test, respectively. SPSS 15.0 software (SPSS, Chicago, IL,
USA) was used to analyze the dat. A 2-sided P<0.05 was
considered as statistically significant.
Results
Clinicopathological Characteristics of IMPC Patients
Among these 100 Chinese IMPC patients, their mean age was
54 years old. Pathologically, 83 cases (83 %) had a tumor size
larger than 2 cm; 90 cases (90 %) showed lymph node metas-
tasis, and 23 (23%) were lymph node grade III, while 89 cases
(89%) had moderate or poor differentiated tumor and 25 cases
(25 %) were triple-negative immune phenotype of tumor.
LZTS1 Expression in IMPC Tissues and Its Association
with Clinicopathological Data from IMPC Patients
LZTS1 protein was expressed in normal breast ductal epithe-
lial tissues with a granular localization in the cytoplasm
(Fig. 1). In contrast, 62 % (62/100) of the IMPC tissue had
LZTS1 protein loss or down-regulation (14 +++, 24 ++, 29 +,
and 33 −) and significantly lower than normal tissues (χ2=
25.655, P=0.000; Table 2).
Moreover, we found that among these different LZTS1
expression from strong to absent level, lymph node metastasis
rate were 71.4 %, 87.5 %, 96.5 %, 93.5 %, respectively. The
expression of LZTS1 protein in IMPC tissue was inversely
associated with IMPC lymph node metastasis (rs=−0.210,
P=0.036) and lymph node grade (rs=−0.265, P=0.008).
However, there was no significant association of LZTS1 ex-
pression with patient age, tumor size, histological grade, ER,
PR and HER2 expression (Table 3).
Table 3 Association of LZTS1 expression with clinicopathological
data from IMPC patients
Clinicopathological character LZTS1 expression rs P value
(−) (+) (++) (+++)
Age (mean age=54)
<54 years old 18 18 7 4
≥54 years old 15 11 17 10 0.222 0.026
Tumor size
<2 cm 4 5 7 1
≥2 cm 29 24 17 13 −0.062 0.541
Histological grade
I 2 1 5 3
II 26 25 16 9
III 5 3 3 2 −0.143 0.155
Lymph node metastasis
− 2 1 3 4
+ 31 28 21 10 −0.210 0.036
Lymph node grade
pN0 2 1 3 4
pN1 7 10 10 5
pN2 14 12 6 3
pN3 10 6 5 2 −0.265 0.008
ER
− 16 8 8 3
+ 17 21 16 11 0.178 0.077
PR
− 6 7 7 5
+ 27 22 17 9 −0.137 0.174
HER2
−/+ 27 22 17 11
++/+++ 6 7 7 3 0.067 0.506
Fig. 2 DNA sequencing data of
MSP products of a pair of IMPC
(T) and normal (N) tissues. A
representative wild-type LZTS1
sequence is shown at the top.
Each of the three cytosines (C) in
a CpG dinucleotide was convert-
ed to thymine (T) in the normal
tissue, but not in the cancer tissue
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LZTS1 Somatic Mutation in IMPC Tissues
We extracted DNA from 100 IMPC paraffin-embedded tis-
sues. However, we could only analyze 53 of the DNA sam-
ples. In IMPC tissue samples, mutations were localized on
exon 3 (C3927G, Leu>Val). Another base change was detect-
ed in the intron region (C6544T) in 25/53 of the IMPC sam-
ples. These changes were not found in the corresponding nor-
mal tissues.
Methylation of LZTS1 Promoter in IMPC Tissues
We analyzed LZTS1 promoter methylation in 18 IMPC sam-
ples, and 9 normal breast tissue samples (as a control). After
MSP, we cloned PCR products into a pGEM-T Easy Vector
and randomly picked ten clones for DNA sequencing from
each tumor sample. Figure 2 shows DNA sequence results
from normal and cancer tissues. Two CG sites were methylat-
ed in the IMPC tumor samples, but not in the normal tissues.
The methylation level for each of the 18 CG dinucleotides
within the PCR product is shown in Fig. 3. We found that
18/18 (100 %) of the IMPC samples had LZTS1 promoter
methylation. In contrast, 0/9 (0 %) of the normal breast tissue
samples had LZTS1 promoter methylation. Furthermore, Sta-
tistical analysis revealed LZTS1 promoter methylation was
associated with the loss of LZTS1 protein expression
(Table 4, P<0.05).
Discussion
In this study, we first detected LZTS1 expression in 100 IMPC
tissues. We found that LZTS1 expression was reduced or lost
in IMPC, and reduced LZTS1 expression was associated with
lymph node metastasis. Many studies have shown that LZTS1
expression is downregulated in different types of human can-
cers, including cancers of the breast, gastric, lung, bladder,
oral cavity, prostate, and kidney [6–13]. In addition, reduced
LZTS1 expression was associated with LZTS1 promoter
methylation or mutation [7, 8]. After that, we determined
whether somatic LZTS1 mutations were associated with clin-
icopathological data from IMPC patients. To date, studies
have detected LZTS1 mutations in different cancers, but they
are uncommon. For example, Ishii H et al. [6] analyzed 194
cancer samples, including 72 primary esophageal cancer sam-
ples, 18 esophageal cancer cell lines, 24 primary prostate can-
cer samples, 3 prostate cancer cell lines, 39 primary breast
cancer samples, 25 breast cancer cell lines, 8 primary ovarian
cancer samples, 4 leukemic cell lines, and 1 cervical cancer
cell line. They found two point mutations in two cases of
esophageal cancer tissues and one point mutation at codon
501 in the prostate cancer PC3 cell line. Vecchione et al. [8]
found a missense mutation in one case of gastric carcinoma
that also had LZTS1 loss. Arnold et al. analyzed LZTS1 coding
regions in 87 primary ovarian adenocarcinoma samples using
DHPLC, but only detected a single silent somatic mutation
[18]. In this study, we also found one of these 53 IMPC sam-
ples had a mutation at exon 3, while 25 of the 53 IMPC
samples had a base change in the intron region of LZTS1.
But LZTS1mutation was not the main cause for loss of LZTS1
expression in IMPC.
Gene promoter methylation is a common epigenetic mech-
anism that transcriptionally inactivates gene expression in dif-
ferent human cancers [19]. Our previous study showed that
LZTS1 promoter methylation was associated with LZTS1
downregulation in IDC [15]. However, LZTS1 promoter was
more frequently methylated in IMPC samples and was asso-
ciated with reduced levels of LZTS1 expression, indicating
that LZTS1 plays a role in promoting IMPC progression at
Fig. 3 LZTS1 promoter
methylation. LZTS1 promoter
methylation level of each of these
18 CpG dinucleotides in IMPC,
and compared to normal breast
tissues (P<0.05)
Table 4 Association between LZTS1 expression and methylation in
IMPC tissues
LZTS1 expression Methylation rs P value
Low Median High
+++ / ++ 3 0 1
− / + 1 2 11 −0.607 0.008
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least through the promoter methylation-mediated transcrip-
tional repressor. Therefore, we hypothesized that reactivation
of the methylation-silenced gene could restore LZTS1 expres-
sion and inhibit IMPC metastasis. The quantitative detection
of LZTS1 might be useful for predicting potential of breast
cancer metastasis. Indeed, our previous study showed that re-
expression of LZTS1 in the highly metastatic MDA-MB-231
cell line resulted in an inhibition of cancer cell proliferation,
migration and invasion, and suppression of epithelial-to-
mesenchymal transition [20]. However, further studies are
needed to confirm this hypothesis.
Our current study is just proof-of-principle and larger sam-
ple sizes are needed to confirm our current data. In addition,
survival data are needed to determine whether there is an
association between LZTS1 expression and overall survival
in IMPC patients. Finally, mechanistic studies are needed to
investigate the mechanism responsible for LZTS1 promoter
methylation and to investigate the role and functions of
LZTS1 protein in IMPC.
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